button bars forest bayes pooled summary circles
 
deaths (OS)

mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)

versus sorafenib
durvalumab plus tremelimumab vs. sorafenib 1 certainty unassessablestatistically conclusive-20%

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons